Compare VRTX & HON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VRTX | HON |
|---|---|---|
| Founded | 1989 | 1885 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Aerospace |
| Sector | Technology | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 115.7B | 120.8B |
| IPO Year | 1991 | N/A |
| Metric | VRTX | HON |
|---|---|---|
| Price | $464.65 | $219.51 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 27 | 12 |
| Target Price | ★ $501.42 | $239.67 |
| AVG Volume (30 Days) | 1.4M | ★ 4.3M |
| Earning Date | 02-12-2026 | 01-29-2026 |
| Dividend Yield | N/A | ★ 2.21% |
| EPS Growth | N/A | ★ 9.45 |
| EPS | ★ 14.22 | 9.47 |
| Revenue | $11,723,300,000.00 | ★ $40,670,000,000.00 |
| Revenue This Year | $10.93 | $5.29 |
| Revenue Next Year | $8.44 | N/A |
| P/E Ratio | $31.08 | ★ $22.70 |
| Revenue Growth | ★ 10.33 | 7.45 |
| 52 Week Low | $362.50 | $179.36 |
| 52 Week High | $519.68 | $241.72 |
| Indicator | VRTX | HON |
|---|---|---|
| Relative Strength Index (RSI) | 55.63 | 69.91 |
| Support Level | $429.00 | $214.20 |
| Resistance Level | $487.52 | $220.63 |
| Average True Range (ATR) | 12.79 | 4.59 |
| MACD | -2.15 | 1.69 |
| Stochastic Oscillator | 57.70 | 94.59 |
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Honeywell traces its roots to 1885 with Albert Butz's firm, Butz Thermo-Electric Regulator, which produced a predecessor to the modern thermostat. Other inventions by Honeywell include biodegradable detergent and autopilot. Today, Honeywell is a global multi-industry behemoth with one of the largest installed bases of equipment. It operates through four business segments: aerospace technologies (37% of 2023 company revenue), industrial automation (29%), energy and sustainability solutions (17%), and building automation (17%). Recently, Honeywell has made several portfolio changes to focus on fewer end markets and align with a set of secular growth trends. The firm is working diligently to expand its installed base, deriving around 30% of its revenue from recurring aftermarket services.